SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is experiencing intense trading activity as market participants debate its potential as a high-volatility, meme-driven asset. While some investors are actively looking for entry points and "loading up" on perceived dips, others remain deeply skeptical, frequently labeling the coin a pump-and-dump scheme or a potential rug pull.

Solphin

Solphin is trending as a low-market-cap meme token gaining traction alongside other aquatic-themed crypto assets. The community is actively discussing its potential for high volatility and price movement while urging platform administrators to address ongoing chart display issues.

Derpy dog on derp.trade 🐶| Long 🟢 and short 🔴 $DERPY with leverage up to 100X on derp.trade! https://app.derp.trade/coin/14bLBcB1iHUBGioLSwjbWBsP26nZKU16Qg44p5Vderp

Derpy

Investors are closely monitoring consistent price consolidation and steady structural movement, fueling community speculation about the asset's potential for future growth.

$FUUU is a Solana-based memecoin that was launched on http://Pump.fun in March 2024. The project is themed around the Rage Guy character, a figure that originated in the rage comic era of the late 2000s and became widely recognized across internet culture. Following the launch, the original developer discontinued involvement with the token. At that point, the CTO team assumed responsibility for coordinating ongoing community efforts around the project.  The stated purpose of $FUUU is cultural rather than financial. It is designed as a “culture coin” that highlights Rage Guy as a symbolic and relatable figure. The character’s expression of frustration, commonly represented by the text “FFFFUUUU,” reflects emotions that are often tied to both cryptocurrency markets and everyday experiences. By building a token around this meme, the project aims to preserve a recognizable piece of internet history within a blockchain context.  Unlike projects that emphasize detailed roadmaps, technical milestones, or defined utility, $FUUU positions itself as a lighthearted and entertainment-driven token. There are no team allocations, no taxes, and no embedded promises of profit or financial return. The coin is intended solely for cultural engagement, community participation, and meme creation. Holders and community members are encouraged to contribute through content, discussion, and the continued use of Rage Guy imagery, but there are no obligations or formal expectations tied to the token.  The CTO team provides organizational support, and back end support such as hiring an artist and creatin websites, the community drives activity associated with the project. This includes creating and sharing memes, maintaining discussion channels, and ensuring the Rage Guy character remains present in contemporary internet culture. The project does not claim utility beyond its role as a culture coin, and its sustainability depends entirely on voluntary participation and ongoing community interest.  From a transparency standpoint, the on-chain parameters of the token are publicly visible. These include the mint authority status, freeze authority, liquidity details (whether burned or locked), and circulating supply information. Any locked or burn addresses are disclosed for the purpose of supporting accurate supply tracking on external platforms.  Rage Guy ($FUUU) should not be viewed as an investment. The token has no intrinsic value and provides no rights, revenue, or guarantees to holders. As with all cryptoassets, trading is highly risky, and participants are advised to conduct their own research and fully understand the risks involved. The project’s focus remains cultural preservation and community expression rather than financial

FUUUUUUUUUUUUUU

FUUU is trending as a highly speculative meme coin, with community members actively discussing its aggressive price swings, rapid scalp potential, and the social sentiment of rebelling against traditional market volatility. While some participants are wary of its status as a high-risk project, many are engaged in coordinated efforts to drive momentum and eliminate price zeros.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph is capturing attention as developers and investors highlight its critical role in Web3 infrastructure, particularly through ongoing integrations with AI agents, cross-chain staking, and high-performance indexing. While community sentiment remains polarized between those viewing it as an oversold utility essential for long-term growth and others frustrated by its historical price performance, the stock remains a frequent subject of speculation regarding a potential breakout as adoption across decentralized networks expands.

Kook Token is a personal, creator-driven streaming token built to revolutionize how people learn about crypto, gaming, and digital culture. Through engaging livestreams, real-talk podcasts, and interactive gameplays, it delivers a raw, unfiltered, and community-first learning experience. Kook Token makes education entertaining — no fluff, just real vibes, alpha drops, and pure fun. Whether you're a beginner or a degen, you'll feel right at home.

kook

KOOK is seeing heightened social media activity and community buzz, driving significant speculative interest across cryptocurrency trading circles.

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is capturing significant attention as investors accumulate the token, viewing its integration into blockchain gaming and on-chain economies as a long-term value play. The community is actively discussing potential reversal patterns and bullish breakouts, with many traders leaning into the narrative that the current price levels represent a prime accumulation zone ahead of anticipated ecosystem growth.

🌍 Introduction: A Legendary Icon, Reimagined for the Future The SEAMANIA Protocol, led by SEAMAN Cult, aims to revive one of SEGA Dreamcast's most iconic and best-selling game titles with AI integration—a worldwide cultural phenomenon that won numerous awards in the U.S. and Japan. More than just a game, SEAMAN was the world’s first AI-powered interactive experience, enabling voice-based conversations long before the AI revolution.    Now, SEAMAN returns not as a mere game, but as an advanced AI agent, blending nostalgia with cutting-edge technology. This human-faced fish is reborn as a deeply intelligent, emotionally responsiveAI, offering limitless customization and integration into the modern digital world.  With GenAI-powered customization, users can create their own SEAMAN AI, shaping it into a cherished lostone, a favorite celebrity, or even historical figures. This is no longer a game—it's an AI-driven personal companion and the digital evolution for human interaction.    🔥 Concept: The Wisdom of a Legendary AI-powered Companion At the core of the SEAMANIA Protocol lies the legendary Seaman—a mystical, human-faced fish endowed withancient wisdom and the ability to understand human language. More than just an AI, it is your trustedadvisor, best friend, therapist, personal cheerleader, witty conversationalist, intelligent guide, SEAMANIA is a life coach. Housed in your own digital aquarium, your SEAMAN AI reduces stress, combats loneliness, and guides humanity towards a brighter future. Imagine an AI companion that doesn’t just respond but truly understands, entertains, and supports you—blending humor, sarcasm, and wisdom.

SEAMANIA

SEAMANIA is trending as traders rotate profits from similar meme-themed assets, driving high-volume activity and intense speculation about potential gains. The community remains deeply divided, with some actively coordinating aggressive buying to trigger rapid growth, while others express concerns regarding the long-term sustainability of these speculative, low-market-cap tokens.

Direxion Shares ETF Trust - Direxion Daily MSFT Bull 2X ETF

Direxion Daily MSFT Bull 1.5X Shares

Investors are actively using MSFU as a leveraged proxy to trade Microsoft's volatility, with the community closely debating entry points, technical support levels, and the sustainability of AI-driven momentum. Sentiment is heavily divided between those aggressively scaling into positions during market dips and others who remain cautious about broader AI sector valuations and potential recessionary headwinds.

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is trending as investors debate the impact of institutional integration and real-world asset tokenization versus broader crypto market volatility. While the community is actively tracking partnerships with major financial firms, sentiment remains divided between those viewing current price levels as a long-term accumulation opportunity and those concerned by ongoing price consolidation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Stifel lowered the firm's price target on DraftKings to $44 from $46.</li><li>Guggenheim has also lowered the firm's price target on DraftKings to $42 from $45.</li><li>JPMorgan said that Gaming stocks "are carrying a lot of baggage and negativity," so investors should be selective.&nbsp;</li></ul>Shares of DraftKings (<a href="https://stocktwits.com/symbol/DKNG">DKNG</a>) fell more than 6% on Friday after several analysts slashed their price targets on the stock ahead of its expected fourth quarter (Q4) earnings results on Monday.&nbsp;<h2 class="st-heading-2">Price Cuts</h2>Stifel lowered the firm's price target on DraftKings to $44 from $46 and kept a ‘Buy’ rating on the shares.The firm said it has approached Q4 earnings for the online gambling group cautiously despite mostly attractive valuations, noting that it tactically favors DraftKings in the near-term given NBA handle share momentum, de-risked consensus FY26 (fiscal year 2026) estimates, potential upside from the Winter Olympics and World Cup.&nbsp;Guggenheim also lowered the firm's price target on DraftKings to $42 from $45 and kept a ‘Buy’ rating on the shares after updating the firm's model for Q4 and "an initially more conservative" 2026 outlook.&nbsp;Given recent guidance challenges, it would be prudent for DraftKings to start 2026 in "a very reasonable zone and hopefully exceed expectations throughout the year," the analyst said in a note.&nbsp;JPMorgan last week also lowered the firm's price target on DraftKings to $41 from $42 and kept an ‘Overweight’ rating on the shares.&nbsp;Gaming stocks "are carrying a lot of baggage and negativity," so investors should be selective, the analyst said.&nbsp;<h2 class="st-heading-2">Upcoming Q4 Earnings</h2>Draftkings is expected to post a revenue of $1.97 billion in Q4, according to data from fiscal.ai.&nbsp;It had missed analyst estimates for third quarter revenue.&nbsp;The company is also expected to report a &nbsp;profit of $0.12 per share in the quarter. It posted a loss of $0.28 per share in the corresponding quarter of 2024.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DKNG trended in ‘neutral’ territory amid ‘high’ message volume.&nbsp;One user said that the gaming segment “is filled with too much risk from all angles.”&nbsp;“And it’s a low margin business to be home with. Risk reward is not in the bulls camp,” they added.<stembedurl>https://stocktwits.com/Balls_deeper/message/643458827</stembedurl>One bullish user said that they are adding more of Draftkings stock amid the selloff.<stembedurl>https://stocktwits.com/howyee1234/message/643455001</stembedurl>Shares in the company have fallen 34% over the past 12 months.&nbsp; &nbsp;

In this photo illustration, the logo of DraftKings Inc. is displayed on a smartphone screen. 

DraftKings Shares Are Falling Today – Here’s Why

Analysts from Stifel, JPMorgan and Guggenheim have slashed their price target on Draftkings ahead of its Q4 earnings due Monday.

Equity

<ul class="summary-bullets"><li>Artemis II is slated to launch no earlier than Feb.6.&nbsp;</li><li>Intuitive will track the radio waves emitted by the Orion spacecraft during the 10-day journey to gauge its real-time position and velocity.&nbsp;</li><li>There are no funds involved in the collaboration.</li></ul>Shares of Intuitive Machines (LUNR) rose over 3% after-hours on Monday after the company said that it was selected by space agency NASA to track the Artemis II Mission.Intuitive is now part of 34 global volunteers chosen by the agency to track the mission around the Moon.The mission, the first of the Artemis program with crew onboard, is slated to launch no earlier than Feb.6.<h2 class="st-heading-2">How Will Artemis Aid The Mission?</h2>Intuitive<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.intuitivemachines.com/post/nasa-selects-intuitive-machines-to-support-tracking-for-artemis-ii"> said</a> that it will support the mission using its Space Data Network (SDN) and ground station infrastructure. The company will track the radio waves emitted by the Orion spacecraft with four astronauts aboard during the 10-day journey to gauge its real-time position and velocity.“In partnership with NASA, tracking Artemis II is another opportunity to strengthen and expand our Space Data Network…We look forward to providing resilient, persistent networking for future Artemis campaign missions and our commercial partners,” said Intuitive Machines CEO Steve Altemus.The company will also submit data to NASA for analysis, helping the agency identify ways to improve future moon and Mars mission support. There are no funds involved in the collaboration, it noted.Past And Future Artemis MissionsIntuitive previously tracked Artemis 1, a crewless mission under the program to the moon. Intuitive tracked the spacecraft then to more than 270,000 miles from Earth, breaking records.Artemis 2 is a key part of NASA’s larger Artemis program aimed at taking humans back to the surface of the moon since after the Apollo program in the 20th century.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around LUNR stock stayed within the ‘bullish’ territory while message volume rose from ‘normal’ to ‘high’ levels.A Stocktwits user termed the stock ‘undervalued.’<stembedurl>https://www.stocktwits.com/Thinking101/message/642944386</stembedurl>Another opined that the company is showing strong growth and demand. “The future here is very large a $100BILLION market cap company in the making,” they wrote.<stembedurl>https://www.stocktwits.com/romanaround/message/642943025</stembedurl><a href="https://stocktwits.com/symbol/LUNR">LUNR stock</a> has fallen 13% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-cvm-shares-rally-today/cmyJRm7R4hj">Why DID CVM Shares Rally Over 7% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Intuitive Machines, Inc. is displayed on a smartphone screen, with the company's blue branding visible in the background, on May 11, 2025, in Chongqing, China.

LUNR Shares Edge Up 3% After Hours — What's Intuitive’s Role In NASA’s Artemis Program?

Intuitive is now part of 34 global volunteers chosen by the agency to track Artemis II. 

<ul class="summary-bullets"><li>Culper believes that T1 is ineligible for 45X tax credits, and forthcoming treasury guidance will be a “death blow” to the company.&nbsp;</li><li>Culper alleged that T1 has rebranded itself as an all American solar module manufacturer while remaining operationally and economically subject to China-based Trina Solar, a foreign entity of concern.&nbsp;</li><li>Culper also noted discrepancies between T1’s reported sales to Trina and Trina’s reported purchases from T1.</li></ul>T1 Energy shares slumped on Wednesday after activist short seller Culper Research published a critical short report on the company and said it has taken a short position against the firm.&nbsp;“We are short T1 Energy, a failed EV battery SPAC that has rebranded itself an all American solar module manufacturer while remaining operationally and economically subject to China-based Trina Solar, a foreign entity of concern (FEOC),” Culper said in its report. &nbsp;“We have little faith in management, nor the Company’s disclosures and financial reporting. T1 is already subject to scrutiny by the U.S. Securities and Exchange Commission, Department of Justice, and U.S. Customs, and we believe faces massive liabilities stemming from these probes, and shares are headed far lower” it said.&nbsp;<h2 class="st-heading-2">Culper’s Allegations</h2>As per Culper’s report, T1 was sued by RWE Clean Energy after RWE terminated its offtake agreement on December 19, 2025. The lawsuit alleged that T1 misrepresented its customer base, failed to provide module audits, failed to deliver compliant modules, and breached confidentiality provisions. Culper also claimed that T1 has not yet disclosed either the termination or the lawsuit.Culper believes that T1 is ineligible for 45X tax credits (Advanced Manufacturing Production Credit) , and forthcoming treasury guidance explicitly designed to “prevent entities from evading, circumventing, or abusing” existing FEOC provisions will be a “death blow.” Experts also warn that certain Chinese groups may be entirely blacklisted, which could risk T1’s eligibility altogether.&nbsp;<h2 class="st-heading-2">Financial Irregularities</h2>Culper also raised irregularities in T1’s financial reporting. It noted discrepancies between T1’s reported sales to Trina and Trina’s reported purchases from T1. As per the report, T1 has accrued $59.7 million due to Trina, which is equivalent to 83% of its total consolidated gross profit for the nine months ended Sept. 2025.Culper Research views T1 as wholly uninvestible. “Absent 45X credits, T1’s business model fails. The Wilmer facility has minimal standalone value without Trina’s materials, operations, personnel, customers, and financial support, and as Treasury enforcement tightens, we believe T1 threatens permanent ineligibility,” it said.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around TE trended in ‘extremely bullish’ territory amid ‘high’ message volume.Shares of the company have risen nearly 11% year-to-date.&nbsp; &nbsp;

T1 Energy shares slumped on Wednesday after activist short seller Culper Research published a critical short report on the company

T1 Energy Dives 12% As Culper Research Takes A Short Position Saying Company Is A ‘Failed EV Battery SPAC’

Culper Research said it has little faith in T1’s management, nor the company’s disclosures and financial reporting and said that shares are headed far lower. 

<ul class="summary-bullets"><li>CEO John C. Jacobs noted that over the past eight quarters, the company has achieved approximately $1.1 billion in non-dilutive cash flow, including $800 million from its partnerships.</li><li>For the third quarter, the company reported total revenue of $70 million, including $48 million from Sanofi, $6 million from Takeda, and $2 million from other partners.</li><li>Novavax now expects full-year adjusted revenue in the $1.04 billion to $1.06 billion range. &nbsp;</li></ul>Novavax (NVAX) CEO John C. Jacobs on Thursday detailed the company’s efforts beyond its COVID-19 vaccine, including expanding partnerships with Sanofi and Takeda.“Our new strategy is centered on amplifying the impact of our technology platform through collaborations with other biopharmaceutical companies and a new diversified pipeline, and this represents a strategic and thoughtful departure away from a single focus on the resource-intense commercialization of one product, our COVID-19 vaccine,” the CEO said.Jacobs noted that over the past eight quarters, the company has achieved approximately $1.1 billion in non-dilutive cash flow, including $800 million from its partnerships in the form of upfront payments and milestones earned to date.The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program. It also renegotiated its deal with Takeda in a bid to grow revenues from the latter's activities involving Nuvaxovid vaccine in Japan.<h2 class="st-heading-2">Q3 Numbers</h2>For the third quarter, the company <a href="https://stocktwits.com/symbol/NVAX">reported</a> total revenue of $70 million, including $48 million from Sanofi, $6 million from Takeda, and $2 million from other partners. This marks a dip from the $80 million reported in the corresponding quarter of 2024, but above an analyst estimate of $44.87 million.The company now expects full-year adjusted revenue in the $1.04 billion to $1.06 billion range, up from its previous guidance of $1 billion to $1.05 billion. This is primarily owing to better than previously expected licensing, royalty, and other revenue.The company’s loss per share came in at $1.25 in the third quarter, above an expected loss of $1.13.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,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" width="623" height="57" alt="NVAX's Sentiment Meter and Message Volume as of 1:12 p.m. ET on Nov. 6, 2025 | Source: Stocktwits"><figcaption>NVAX's Sentiment Meter and Message Volume as of 1:12 p.m. ET on Nov. 6, 2025 | Source: Stocktwits</figcaption></figure>NVAX stock is down by about 4% this year and by about 14% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-reportedly-refrains-from-backing-down-in-metsera-acquisition-battle-sweetens-bid-further/cL2twEeRER8">Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax Sees Higher Revenue From Partners For Full-Year, Raises Revenue Guidance

The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program.

The company recently expanded on its Sanofi partnership to include its Matrix-M adjuvant in Sanofi’s pandemic influenza vaccine candidate program and renegotiated its deal with Takeda in a bid to grow revenues from the latter's activities involving Nuvaxovid vaccine in Japan. 

<ul class="summary-bullets"><li>In Q3, Ibsrela saw highest demand since launch and recorded revenue of $78.2 million, marking a growth of 92%.</li><li>Ardelyx’s net loss in the quarter, however, was $1 million, compared to net loss of $0.8 million reported in the corresponding quarter of 2024.</li><li>The company is now looking forward to filing an investigational new drug submission to the FDA for its early-stage candidate RDX10531 in 2026.&nbsp; &nbsp;</li></ul>Ardelyx shares soared 22% in Friday’s premarket session after the company raised guidance for its irritable bowel syndrome drug Ibsrela, which saw the highest demand in the third quarter (Q3).“IBSRELA continues to outperform and is the foundation of our portfolio and the main engine for Ardelyx's future growth,” CEO Mike Raab said on the company’s earnings call on Thursday.“Demand growth is broad-based and demonstrates how vital this therapy is for patients. We expect this momentum to continue through Q4 and beyond, and as a result, we are raising our guidance,” he added.<h2 class="st-heading-2">Revised Guidance, Q3 Fineprint</h2>The company now <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.ardelyx.com/news-releases/news-release-details/ardelyx-reports-third-quarter-2025-financial-results-and">expects </a>revenue to be between $270 million and $ 275 million from Ibsrela for the full year. In the third quarter, the drug generated revenue of $78.2 million, marking a growth of 92%, and accounting for 74% of the company’s total product revenue for the period.U.S. revenue for Xphozah, used to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis, was $27.4 million in Q3 despite dynamic market situations, the company said. Ardelyx now expects continued growth in the fourth quarter for the drug.Total revenue in the quarter, including product and licensing revenue, came in at $110.3 million, above an analyst estimate of $100.54 million. Net loss in the quarter was $1 million, slightly wider than the $0.8 million net loss reported in the corresponding quarter of 2024.<h2 class="st-heading-2">Future Pipeline</h2>In the third quarter, Ardelyx began developing RDX10531, an early-stage drug candidate. The company is now looking forward to filing an Investigational New Drug submission with the U.S. Food and Drug Administration for the candidate in 2026, to initiate trials in humans.“We are committed to building a broad, sustainable pipeline, capitalizing first on an internal asset while, in parallel, we explore external opportunities,” Raab said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ARDX">ARDX stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:623/57;" src="data:image/png;base64,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" width="623" height="57" alt="ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits"><figcaption>ARDX's Sentiment Meter and Message Volume as of 8:50 a.m. ET on Oct. 31, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user sees the stock hitting a per-share price of $7 today.<stembedurl>https://stocktwits.com/badgermobile/message/634454149</stembedurl>Another expressed optimism about the CEO saying on the earnings call that it is open to external business opportunities.<stembedurl>https://stocktwits.com/Dragan7/message/634447443</stembedurl>ARDX stock is down 1% year-to-date and by approximately 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-shareholder-gavin-baker-supports-elon-musk-1-trillion-pay-plan/cLGqGXNR3Ul">Atreides’ Gavin Baker Backs Elon Musk’s $1T Tesla Pay Deal Despite Broad Opposition</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Ardelyx logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Ardelyx Shares Soar Premarket As CEO Sees Continued Demand For Blockbuster Drug Ibsrela

The company now expects revenue from Ibsrela to be between $270 million and $275 million for the full year.

<ul class="summary-bullets"><li>ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study.</li><li>Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company said.&nbsp;</li><li>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome.&nbsp; &nbsp;</li></ul>Aldeyra Therapeutics, Inc. (ALDX) on Tuesday announced that its experimental drug candidate ADX-629 demonstrated statistically significant improvement in liver function in patients with alcohol-associated hepatitis in a mid-stage trial.ADX-629 was administered orally for one month in four patients with mild to moderate alcohol-associated hepatitis in the study. Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-results-phase-2-clinical">said.</a>No serious adverse events were reported in the trial, the company noted. Furthermore, no adverse events were deemed related to its experimental drug, it added.<h2 class="st-heading-2">Plans Ahead</h2>The company has, however, &nbsp;now discontinued clinical development of ADX-629 pending further investigator-sponsored clinical testing in Sjögren-Larsson Syndrome, a rare genetic disorder.CEO Todd C. Brady said that the company will share details of the recent trial in the future and will now focus its pipeline on ADX-248 and ADX-246 for the treatment of immune-mediated diseases.While ADX-248 is being studied in the treatment of metabolic inflammation, including obesity and hypertriglyceridemia, ADX-246 is being studied for the treatment of dry form of age-related macular degeneration.Aldeyra is committed to developing a robust pipeline of novel therapeutics in a fiscally prudent manner to maintain growth, the CEO noted.The company now expects cash, cash equivalents, and marketable securities to provide operational runway into the second half of 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels.ALDX stock is down by 0.5% this year and by about 12% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-registrations-slumped-nearly-19-percent-in-eu-in-september-despite-rising-ev-demand/cLGjW7LR3HL">Tesla Registrations Slumped Nearly 19% In EU In September Despite Rising EV Demand</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Aldeyra Reports Positive Mid-Stage Data For Liver Drug, Discontinues Further Development

Statistically significant improvement relative to baseline was observed in clinically relevant objective markers of hepatic function and inflammation in the study, the company said. 

<ul class="summary-bullets"><li>Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.</li><li>In the study, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo, more than doubling median progression-free survival to 5.52 months.</li><li>According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma. &nbsp;</li></ul>Shares of Inhibrx Biosciences (INBX) jumped over 62% in the pre-market session on Friday after the company announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.The company investigated Ozekibart as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma, a rare type of bone cancer that develops in the cartilage cells, most often affecting the pelvis, thigh, or upper arm.<h2 class="st-heading-2">What Was Observed In The Study?</h2>In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://inhibrxbiosciences.investorroom.com/2025-10-23-Inhibrx-Biosciences-Reports-Positive-Topline-Results-from-its-Registrational-Trial-of-Ozekibart-INBRX-109-in-Chondrosarcoma-and-Provides-Updates-on-Colorectal-Cancer-and-Ewing-Sarcoma-Expansion-Cohorts">study</a>, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared with placebo, more than doubling median progression-free survival to 5.52 months versus 2.66 months with placebo. Progression-free survival (PFS) is the time a patient lives with a disease without worsening, from the start of treatment until disease progression or death.According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma.<h2 class="st-heading-2">Safety Concerns</h2>Ozekibart was generally well tolerated, with a manageable safety profile, the company said. However, one liver damage-related fatal event occurred early in the study, it noted. The company mitigated the risk during the course of the trial by excluding patients with severe liver impairment and by implementing close monitoring during early treatment cycles, thereby reducing the overall incidence of liver-related treatment-related adverse events, it added.Inhibrx is also studying the drug in colorectal cancer and ewing sarcoma in combination with other drugs. While colorectal cancer is a cancer that forms in the colon or rectum, ewing sarcoma is a type of cancer that forms in the bone or soft tissue.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/INBX"> INBX stock </a>jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels. Retail chatter around the stock jumped about 985% over the past 24 hours, according to Stocktwits data.<figure class="image"><img style="aspect-ratio:584/62;" src="data:image/png;base64,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" width="584" height="62" alt="INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>INBX's Sentiment Meter and Message Volume as of 7:00 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to rally as high as over $70, citing the company’s first-mover advantage in developing drugs for chondrosarcoma.<stembedurl>https://stocktwits.com/spaumaki/message/633545900</stembedurl>INBX stock is up 84% this year.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/reliance-increases-crude-imports-from-middle-east-u-s-amid-russian-crude-sanctions-report/cLGJZgVR3so">Reliance Increases Crude Imports From Middle East, U.S. Amid Russian Crude Sanctions: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Is INBX Stock Rising Today?

Inhibrx Biosciences announced that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.

EMJ Capital President Eric Jackson on Wednesday expressed optimism about Sana Biotechnology (SANA) stock, saying it could become “the next 100-bagger platform.”SANA shares traded 35% higher at the time of writing.Jackson <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/ericjackson/status/1978460243001782649">took</a> to the social media platform X, opining that <a href="https://stocktwits.com/symbol/SANA">SANA stock</a> would eventually explode, and highlighted the company’s various achievements, including its work in type 1 diabetes treatment. In January, Sana said that following a transplant of an allogeneic primary islet cell therapy into a patient with type 1 diabetes, they started producing insulin. The therapy was engineered with Sana’s hypoimmune (HIP) technology, enabling the transplantation without the need for immunosuppression.<figure class="image"><img style="aspect-ratio:592/407;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_15_at_11_35_05_AM_png_c72bd5dfe0.webp" alt="Screenshot 2025-10-15 at 11.35.05 AM.png" width="592" height="407"><figcaption>Screenshot of Jackson's X Post</figcaption></figure>Transplants generally require lifelong immunosuppression, but Sana’s technology removes the need for them, Jackson noted. ‘That’s not hype — it’s human proof that Sana’s “hypoimmune” cells can hide from the immune system and work normally. If it works in diabetes, it could work for liver, heart, muscle, or brain cells next,’ he wrote, expressing hopes for the technology powering future therapies for autoimmune diseases, cancer, and even organ regeneration.Jackson further highlighted that the biotech company’s balance sheet is solid and added that he was long on SANA stock. He also highlighted several upsides, including 9 million people with diabetes worldwide who might benefit from the treatment.“If Sana’s therapy costs $100K per patient (typical for cell therapy) and reaches only 10% of them, that’s $90B in revenue potential over time,” Jackson said.On Stocktwits, retail sentiment around SANA jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped from ‘high’ to ‘extremely high’ levels.SANA stock has more than tripled this year and gained about 41% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/astrazeneca-unveils-expanded-facility-in-texas-aimed-at-doubling-production-of-hyperkalemia-drug/ch6nzBiR3No">AstraZeneca Unveils Expanded Facility In Texas Aimed At Doubling Production Of Hyperkalemia Drug</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’

Jackson added that he was long on the stock, while highlighting that the biotech company’s balance sheet is solid.

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

Larimar Therapeutics, Inc. (LRMR) on Monday announced positive data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.Friedreich's Ataxia (FA) is a rare, inherited disorder causing progressive damage to the nervous system, leading to symptoms like poor coordination, difficulty walking, and sensory loss, as well as heart disease and scoliosis. It is caused by a mutation in the FXN gene, resulting in a deficiency of the mitochondrial protein frataxin.In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html">study,</a> an increase in skin frataxin (FXN) levels was observed with short- and long-term daily Nomlabofusp. All ten participants with data at six months achieved skin FXN levels over 50% of median levels in healthy volunteers, the company stated. It added that consistent directional improvement across multiple clinical outcomes was also observed after a year of Nomlabofusp treatment.“These new data, as well as the improvement in abnormal lipid profiles observed in prior completed studies, provide support that nomlabofusp increases FXN in patients with FA and that the strategy of FXN replacement has the potential to result in a clinical benefit,” said CEO Carole Ben-Maimon.Shares of the company tumbled 47% in the pre-market session after the company reported that anaphylaxis, or a severe allergic reaction, was observed in seven participants in the open-label study, and they were subsequently withdrawn from the study. Most instances of anaphylaxis occurred on the initial day of administration and most within the first six weeks of dosing, it noted.Other discontinuations in the study included three cases of generalized urticaria, one seizure, one vasovagal event, and two non-treatment-related discontinuations, it said.The company said that it consulted experts and decided to modify its starting dose regimen after the two most recent cases of anaphylaxis. The U.S. Food and Drug Administration has agreed with the approach, the company said. Larimar is looking to submit an application for approval of Nomlabofusp to the FDA in the second quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.LRMR stock is down by 2% this year and by 42% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study

The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia. 

iShares Trust - iShares Russell 3000 ETF

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$361.62
Prev Close	$367.98
Open	$366.44
Dividend Yield	N/A
50-Day Moving Average	$386.66
Beta	N/A
Avg. Volume	285,133.91
PE Ratio	N/A

52-Week High	$397.05
52-Week Low	$273.60
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

IWV
BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWV News

IWVBlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF